Marketing attribution for enterprise revenue teams for healthcare and life sciences in North America

This edition of the Growth Broker playbook is written for commercial leaders at healthtech, medtech, and life-sciences companies operating in North America. In this market, the North American B2B buyer is saturated with vendor outreach and rewards specificity, category clarity, and speed, so the way you install marketing attribution has to be shaped to that reality from day one.

Enterprise marketing attribution is not a bigger version of the startup playbook. It is the honest answer to which activities create pipeline, run under governance, procurement, and regional constraints most founders never encounter.

The value of marketing attribution at enterprise scale is compounded by distribution: you cannot allocate spend against a number you don't trust, and applied across dozens of teams the delta becomes a full quarter of pipeline.

The right shape at enterprise is a hub-and-spoke: a central team owns the model, the metric, and the tooling; regional teams own execution against local ICP nuance. Fully centralised deployments miss context; fully federated deployments diverge inside a quarter.

Inside healthcare and life sciences, the binding constraint is almost always regulated-sale cycle length, not intent, and in North America it is compounded by the fact that signal above noise, not lead volume is what actually gates growth. Marketing attribution is only useful here when it is pointed at both constraints at once.

Instrument attribution model reconciled to closed-won as a shared metric across BUs before you argue about incentives. Anything less turns the operating review into a data debate instead of a revenue conversation.

The enterprise-specific failure mode is picking a model to defend a budget instead of to learn, magnified by the fact that governance rewards process compliance over outcome. Design controls that catch the trap without slowing the model.

Rollout takes two quarters, not two months. Pilot with one BU that already has strong ops. Publish a scorecard. Then expand — never in parallel across five regions at once.

Enterprise marketing attribution done right is the difference between a decade of predictable growth and a decade of restructures. Done wrong, it becomes another initiative buried under next year's slide.

Concretely for healthcare and life sciences in North America: the healthcare teams that install this get past procurement instead of dying in it, and the North American teams that install this land inside the first quarter, not the fourth. That is the reason it is worth installing marketing attribution deliberately for this market rather than importing a playbook designed for somewhere else.